Project Grant R21AG084931
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $199,258 to the Oklahoma Medical Research Foundation (OMRF) to determine the influence of metformin treatment on mitochondrial calcium flux during aerobic exercise training in healthy, aging rats. The key objectives are to: 1) assess how metformin treatment alters mitochondrial calcium kinetics during aerobic exercise training, and 2) evaluate if metformin treatment during training affects the...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $425,958 to the University of Arizona to study the role of the hormone glucagon in mediating the health and longevity benefits of calorie restriction in humans. The key objectives are to: 1) Measure serum levels of glucagon, glucagon-like peptide-1 (GLP-1), and fibroblast growth factor 21 (FGF21) in participants of the CALERIE calorie restriction trial at baseline, 12 months, and 24 months...
- The U.S. National Institute on Aging awarded a $467,416 Project Grant (R21AG085086) to Tufts University School of Medicine to investigate the effects of calorie restriction on mitochondrial DNA integrity and its relationship to biological aging and cardiometabolic health. The study will analyze mitochondrial DNA heteroplasmy changes over two years in participants from the CALERIE clinical trial, which examined the long-term effects of calorie restriction. The project aims to determine if calorie...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $1,339,717 to Ridgeline Therapeutics LLC to conduct preclinical validation of a novel small molecule drug to prevent muscle loss and enhance weight loss in older adults. The funding supports research and development of compounds that inhibit nicotinamide N-methyltransferase (NNMT), a validated target for addressing obesity, age-related muscle degeneration, and related metabolic conditions. Key...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $595,472 in funding to the University of Wisconsin-Madison to conduct research on understanding the roles of prolonged fasting, calorie intake, and the mTORC1 protein kinase in the response to calorie restriction. The research aims to elucidate the physiological and molecular mechanisms by which calorie restriction influences metabolism, healthspan, and longevity, with a focus on potential...
- This $120,573 federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) supports research by Dr. Matthew D. Campbell at the University of Washington to investigate dysfunctional redox-sensitive signaling mechanisms in aged skeletal muscle that impact metabolic function following exercise. The research aims to: 1) establish how dysfunctional redox signaling alters substrate utilization after exercise, 2) determine the impact on beta-oxidation and TCA cycle...
- This Project Grant award of $110,726.00 from the Department of Health and Human Services National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) aims to utilize data from the Molecular Transducers of Physical Activity Consortium (MoTrPAC) to characterize the molecular aging of white adipose tissue and the potential impact of endurance exercise training, with a focus on sex-specific differences. The research project led by the Pacific Northwest National...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $386,900.00 to the University of Texas Health Science Center at Houston (UTHealth) to study the role of the circadian clock and retinoid acid receptor-related orphan receptor (ROR) proteins in regulating metabolic function and healthy aging. The key objectives are to: 1) Evaluate the impact of ROR proteins on healthspan and lifespan using mice with skeletal muscle-specific ROR knockout, 2)...
- This federal Project Grant award of $2,602,940 from the National Institute on Aging (CFDA 93.866 Aging Research) supports research conducted by the Oklahoma Medical Research Foundation (OMRF) to investigate the role of mitochondrial AMPK signaling in neurons and its impact on dendritic spine maintenance. The research aims to determine the molecular composition and dynamics of mitochondrial-localized AMPK complexes (mitoAMPK) in Alzheimer's disease (AD) neurons, as well as establish mitoAMPK's...
- This $644,864 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports preclinical studies by Ridgeline Therapeutics LLC, a Houston-based biotech company, to evaluate the efficacy of their lead compound RT-002 in preventing and reversing disuse-induced muscle atrophy in aging rat models. Specifically, the project aims to determine if RT-002 treatment can mitigate the loss of muscle mass and strength during muscle disuse, as well as improve the rate...
NON-CANONICAL MECHANISMS AND UNCONVENTIONAL APPROACHES TO ACTIVATE AMPK AND GLUCOSE UPTAKE IN THE SKELETAL MUSCLE OF OLDER RATS - AMP-ACTIVATED PROTEIN KINASE (AMPK) IS A HIGHLY CONSERVED SERINE/THREONINE KINASE WITH MANY IMPORTANT EFFECTS, INCLUDING PUTATIVE ANTI-AGING ACTIONS. AMPK PLAYS A KEY ROLE IN THE CONTROL OF GLUCOSE UPTAKE BY SKELETAL MUSCLE, THE TISSUE THAT ACCOUNTS FOR UP TO 85% OF INSULIN-INDUCED BLOOD GLUCOSE CLEARANCE. INSULIN RESISTANCE FOR MUSCLE GLUCOSE UPTAKE IS AN ESSENTIAL DEFECT FOR TYPE 2 DIABETES AND LINKED TO MANY OF THE MOST PREVALENT AND DEVASTATING AGE-RELATED PATHOLOGIES, INCLUDING CARDIOVASCULAR DISEASE AND COGNITIVE DYSFUNCTION. CALORIC RESTRICTION (CR; REDUCING CALORIE INTAKE 20-40% BELOW AD LIBITUM INTAKE) ENHANCES INSULIN-STIMULATED GLUCOSE UPTAKE IN MUSCLE OF OLD RATS. THE BROAD, LONG-TERM GOAL OF THIS PROJECT IS TO ADVANCE UNDERSTANDING OF MECHANISMS TO IMPROVE INSULIN SENSITIVITY, LEADING TO HEALTHY AGING. THE SPECIFIC AIMS ARE: 1) TO DETERMINE CR EFFECTS ON KEY ALLOSTERIC REGULATORS OF AMPK, AND ON THE ACTIVATION OF AMPK IN SELECTED SUBCELLULAR COMPARTMENTS OF SKELETAL MUSCLE FROM OLDER RATS; AND 2) TO ASCERTAIN ALDOMETANIB (A RECENTLY DISCOVERED AMPK ACTIVATOR) EFFECTS ON OLDER RAT SKELETAL MUSCLE SUBCELLULAR LOCALIZATION OF AMPK T172 PHOSPHORYLATION, GLUCOSE UPTAKE, CELL SURFACE GLUT4 LOCALIZATION, AND KEY SIGNALING PROTEINS. CR BY OLDER RATS LEADS TO GREATER PHOSPHORYLATION OF AMPK ON THE KEY REGULATORY T172 SITE (PAMPKTHR172) CONCOMITANT WITH GREATER PHOSPHORYLATION OF MULTIPLE AMPK SUBSTRATES IN MUSCLE INDEPENDENT OF CHANGES IN MUSCLE ATP OR AMP, THE MAJOR ALLOSTERIC REGULATORS OF AMPK. BECAUSE CONVENTIONAL MECHANISMS CANNOT EXPLAIN THESE STRIKING RESULTS, THIS PROJECT WILL PROBE NON-CANONICAL MECHANISMS, INCLUDING THE MUSCLE CONCENTRATION OF FRUCTOSE-1, 6- BISPHOSPHATE THAT INCREASES PAMPKTHR172 BY AN AMP-INDEPENDENT MECHANISM. AMPK RESIDES IN MULTIPLE COMPARTMENTALIZED POOLS, AND SPATIAL REGULATION OF AMPK IS A CRUCIAL DETERMINANT OF FUNCTION, YET NO EARLIER CR RESEARCH ANALYZED COMPARTMENTALIZED AMPK ACTIVATION. ACCORDINGLY, CR EFFECTS ON SUBCELLULAR LOCALIZATION OF PAMPKTHR172 AND PHOSPHORYLATION OF AMPK SUBSTRATES WILL BE EVALUATED. ALTHOUGH CR IMPROVES INSULIN SENSITIVITY, ITS WIDESPREAD ADOPTION BY HUMANS IS UNREALISTIC. IDENTIFICATION OF SAFE AND EFFECTIVE ALTERNATIVE INTERVENTIONS IS ESSENTIAL. A NOVEL ALDOLASE INHIBITOR (ALDOMETANIB) SELECTIVELY INCREASED LYSOSOMAL PAMPKTHR172 WITHOUT ALTERING PAMPKTHR172 IN OTHER SUBCELLULAR LOCATIONS, AND ALSO WITHOUT ALTERING THE CONCENTRATIONS OF AMP OR ATP IN CULTURED CELLS. BECAUSE THE SPECIFIC MECHANISMS WHEREBY ALDOMETANIB ELEVATES GLUCOSE UPTAKE ARE UNKNOWN, THIS PROJECT WILL DETERMINE ALDOMETANIB'S EFFECTS ON SUBCELLULAR LOCALIZATION OF PAMPKTHR172, GLUT4 TRANSPORTER TRANSLOCATION, AND REGULATION OF KEY SIGNALING PROTEINS THAT REGULATE GLUCOSE UPTAKE IN THE SKELETAL MUSCLE OF OLDER RATS. THIS STUDY WILL CHALLENGE CONVENTIONAL WISDOM ABOUT CR'S REGULATION OF AMPK, AND REVEAL VALUABLE INSIGHTS INTO A PROMISING, NEW AMPK ACTIVATOR'S MECHANISMS AND ACTIONS ON MUSCLE GLUCOSE UPTAKE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $429.0k | 6/25/24 |